Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease
Status:
RECRUITING
Trial end date:
2027-10-19
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight and proportion of participants with 5% reduction in body weight.